Patient Adherence and Compliance

$995.00

Use this report to build or reinforce your company’s patient adherence and compliance programs. Detailed benchmarking data will guide patient focused organizations to marshal critical financial and staffing resources, choose appropriate channels and tools, and drive implementation across markets. Track the departments and subfunctions involved in the development of dedicated patient groups, and understand their structures and reporting lines. Along the way, explore insights from leading executives as they manage the difficult evolution toward patient-centric operations — and discover best practices to overcome common external and internal hurdles to adherence.

Download a benchmarking report summarySpeak to a pharmaceutical benchmarking expert

Report Details

Publication Date: March 2012
Pages: 153
Chapters: 4
Metrics: 500+
Charts/Graphics: 100+

Top Reasons to Buy this Patient Adherence and Compliance Report

Build Strong Programs: Patient engagement ultimately comes down to effective programs. Use the report’s benchmark data to marshal critical financial and staffing resources, choose appropriate channels and tools, and drive implementation across markets.

Empower Patient Adherence Teams: Dedicated patient adherence teams increase any organization’s ability to understand end users and address real consumers’ wants, needs and fears. Track the departments and subfunctions involved in the development of dedicated groups, and understand their structures and reporting lines.

Formulate Patient-Centric Strategy: Look inside companies as they manage the difficult evolution toward patient-centric operations — and explore common external and internal challenges that face any group trying to improve patient engagement.

This benchmarking report provides strategy and detail that enables patient-focused organizations to build or reinforce their patient adherence and compliance programs.

You may also be interested in CEIConnect: The Lifesciences Industry’s On-Demand Research Resource as well as our individual marketing research reports.

Excerpt from Patient Adherence and Compliance

Each year, an estimated $290 billion is lost in the US due to nonadherence, and countless hospitalizations or deaths that could have been prevented with proper treatment are not Low adherence rates plague all stakeholders in the healthcare system, including life science companies, payers and patients, who fail to realize the benefits of their prescribed treatment plans.

Companies develop patient adherence programs as a way to address this issue and to support consumers using their products. By bolstering adherence and compliance initiatives, dedicating more resources to patient engagement and building infrastructure to manage patient relationships, organizations in the pharmaceutical, biotechnology and medical technology spaces are prioritizing patient-focused activity

Table of Contents

9              Executive Summary

14           Patient Adherence: Five Recommendations and Key Findings

23           Structural Approaches to Adherence and Compliance

25           Patient Engagement Team Structure

39           Outsourcing Adherence Activities

45           Adherence Budgets, Channels and Activities

75           Patient Program Challenges and Strategy

81           Key Challenges to Patient Programs

88           Patient-Centrism as Strategy

95           Winning Internal Support

101         Implementing Strategy

111         Profiles of Patient Adherence Programs

153         Endnotes

Charts and Graphics

Executive Summary

Patient Adherence: Five Recommendations and Key Findings

16           Figure E.1: Number of Companies with a Team Dedicated to Adherence Programs

18           Figure E.2: Adherence Budgets, 2009–2012

19           Figure E.3: Change in Budgets for Adherence Channels, 2011 to 2012

Structural Approaches to Adherence and Compliance

Patient Engagement Team Structure

25           Figure 1.1: Percentage of Companies with a Team Dedicated to Adherence Programs

26           Figure 1.2: US: Percentage of Companies with a Team Dedicated to Adherence Programs

26           Figure 1.3: EU/Canada: Percentage of Companies with a Team Dedicated to Adherence Programs

28           Figure 1.4: Groups Involved in Adherence Efforts (All Companies)

30           Figure 1.5: US: Groups Involved in Adherence Efforts

30           Figure 1.6: EU/Canada: Groups Involved in Adherence Efforts

31           Figure 1.7: Asia Pacific: Groups Involved in Adherence Efforts

32           Figure 1.9: US: Group with Final Decision-Making Responsibility for Adherence Programs

32           Figure 1.8: Group with Final Decision-Making Responsibility for Adherence Programs (All Companies)

33           Figure 1.10: EU/Canada: Group with Final Decision-Making Responsibility for Adherence Programs

33           Figure 1.11: Asia Pacific: Group with Final Decision-Making Responsibility for Adherence Programs

36           Figure 1.12: FTEs Focused on Adherence Programs, by Department (All Companies)

36           Figure 1.13: US: FTEs Focused on Adherence Programs, by Department

37           Figure 1.14: EU/Canada: FTEs Focused on Adherence Programs, by Department

37           Figure 1.15: Asia Pacific: FTEs Focused on Adherence Programs, by Department

39           Figure 1.16: Percentage of Companies that Outsource Adherence Program Work

Outsourcing Adherence Activities

40           Figure 1.17: US: Percentage of Companies that Outsource Adherence Program Work

40           Figure 1.18: EU/Canada: Percentage of Companies that Outsource Adherence Program Work

41           Figure 1.19: Asia Pacific: Percentage of Companies that Outsource Adherence Program Work

Adherence Budgets, Channels and Activities

46           Figure 2.1: Percentage of Companies with a Budget Dedicated to Adherence Programs

47           Figure 2.2: US: Percentage of Companies with a Budget Dedicated to Adherence Programs

48           Figure 2.3: EU/Canada: Percentage of Companies with a Budget Dedicated to Adherence Programs

49           Figure 2.4: Adherence Budgets, 2009-2012 (All Companies)

51           Figure 2.5: US Adherence Budgets, 2009-2012

52           Figure 2.6: EU/Canada Adherence Budgets, 2009–2012

53           Figure 2.7: Asia Pacific Adherence Budgets, 2009–2012

54           Figure 2.8: Percentage of 2012 Budget Dedicated to Overhead

57           Figure 2.9: Percentage of 2012 Budget Dedicated to Different Adherence Program Channels (All Companies)

58           Figure 2.10: US: Percentage of 2012 Budget Dedicated to Different Adherence Channels

59           Figure 2.11: EU/Canada: Percentage of 2012 Budget Dedicated to Different Adherence Program Channels

60           Figure 2.12: Asia Pacific: Percentage of 2012 Budget Dedicated to Different Adherence Program Channels

61           Figure 2.13: Percentage of 2012 Budget Dedicated to Specific Digital Tools

62           Figure 2.14: Change in Budgets from 2011 to 2012 for Specific Digital Tools

65           Figure 2.15: Percentage of 2012 Budget Dedicated to Specific Mobile Tools

66           Figure 2.16: Change in Budgets from 2011 to 2012 for Specific Mobile Tools

67           Figure 2.17: Percentage of 2012 Budget Dedicated to Specific Print Tools

68           Figure 2.18: Change in Budgets from 2011 to 2012 for Specific Print Tools

69           Figure 2.19: Percentage of 2012 Budget Dedicated to Involvement with Patient Organizations

71           Figure 2.20: Change in Budgets from 2011 to 2012 forInvolvement with Patient Organizations

72           Figure 2.21: Percentage of 2012 Budget Dedicated to Patient Access Activities

73           Figure 2.22: Change in Budgets from 2011 to 2012 forPatient Access Activities

Patient Program Challenges and Strategy

76           Figure 3.1: Percentage of Drug Sales Lost in 2011 Due to Patient Non-Adherence

77           Figure 3.2: Percentage of Revenue Preserved by Patient Adherence Efforts

78           Figure 3.3: The Cost of Patient Acquisition (All Regions)

79           Figure 3.4: US: Cost of Patient Acquisition

79           Figure 3.5: EU/Canada: Cost of Patient Acquisition

80           Figure 3.6: Asia Pacific: Cost of Patient Acquisition

Key Challenges to Patient Programs

82           Figure 3.7: External Communications Challenges to Adherence Efforts (All Companies)

82           Figure 3.8: US Rankings of External Communications Challenges to Adherence Efforts

83           Figure 3.9: EU/Canada Rankings of External Communications Challenges to Adherence Efforts

83           Figure 3.10: Asia Pacific Rankings of External Communications Challenges to Adherence Efforts

84           Figure 3.11: Operational Challenges to Adherence Efforts (All Companies)

85           Figure 3.12: US Rankings of Operational Challenges to Adherence Efforts

85           Figure 3.13: EU/Canada Rankings of Operational Challenges to Adherence Efforts

86           Figure 3.14: Asia Pacific Rankings of Operational Challenges to Adherence Efforts

Winning Internal Support

96           Figure 3.15: Metrics Used to Gauge Success of Adherence Programs

101         Figure 3.16: Point at Which Adherence Strategy Planning Begins

Implementing Strategy

102         Figure 3.17: Social Media Avenues Used by Companies

103         Figure 3.18: Percentage of Companies Using Unique Technologies (Medical Devices, Packaging, etc.) to Drive Adherence

104         Figure 3.19: Patient Outreach Activities Most Likely to Increase in the Next Five Years

105         Figure 3.20: Patient Outreach Activities Most Likely to Decrease in the Next Five Years

Profiles of Patient Adherence Programs

114         Figure 4.1: Background and Structure for Company B

115         Figure 4.2: Adherence Team Resources: Company B

116         Figure 4.3: Adherence Team Strategy: Company B

117         Figure 4.4: Ratings of Challenges: Company B

118         Figure 4.5: Background and Structure for Company D

119         Figure 4.6: Adherence Team Resources: Company D

120         Figure 4.7: Adherence Team Strategy: Company D

121         Figure 4.8: Ratings of Challenges: Company D

122         Figure 4.9: Background and Structure for Company E

123         Figure 4.10: Adherence Team Strategy: Company E

124         Figure 4.11: Ratings of Challenges: Company E

125         Figure 4.12: Background and Structure for Company G

126         Figure 4.13: Adherence Team Resources: Company G

127         Figure 4.14: Adherence Team Strategy: Company G

128         Figure 4.15: Ratings of Challenges: Company G

129         Figure 4.16: Background and Structure for Company M

130         Figure 4.17: Adherence Team Resources: Company M

131         Figure 4.18: Adherence Team Strategy: Company M

132         Figure 4.19: Ratings of Challenges: Company M

133         Figure 4.20: Background and Structure for Company N

134         Figure 4.21: Adherence Team Resources: Company N

135         Figure 4.22: Adherence Team Strategy: Company N

136         Figure 4.23: Ratings of Challenges: Company N

137        Figure 4.24: Background and Structure for Company P

138         Figure 4.25: Adherence Team Resources: Company P

139         Figure 4.26: Adherence Team Strategy: Company P

140         Figure 4.27: Ratings of Challenges: Company P

141         Figure 4.28: Background and Structure for Company Q

142         Figure 4.29: Adherence Team Resources: Company Q

143         Figure 4.30: Adherence Team Strategy: Company Q

144         Figure 4.31: Ratings of Challenges: Company Q

145         Figure 4.32: Background and Structure for Company R

146         Figure 4.33: Adherence Team Resources: Company R

147         Figure 4.34: Adherence Team Strategy: Company R

148         Figure 4.35: Ratings of Challenges: Company R

149         Figure 4.36: Background and Structure for Company S

150         Figure 4.37: Adherence Team Resources: Company S

151         Figure 4.38: Adherence Team Strategy: Company S

152         Figure 4.39: Ratings of Challenges: Company S

Endnotes